OBJECTIVE: To examine the incidence and prognostic value of circulating tumor cells (CTCs) in urothelial cancer (UC). The detection of CTCs is prognostic in several cancer types. METHODS: A total of 44 subjects with UC were assessed for CTCs using CellSearch Technology and 7.5 mL of peripheral blood, sorted by magnetic separation (epithelial cell adhesion molecule positive) and immunofluorescent staining (positive for cytokeratin 8, 18, or 19, negative for CD45, positive for 4',6-diamidino-2-phenylindole) to identify the CTCs. RESULTS: Five (17%) of 30 subjects with clinically localized and 7 (50%) of 14 subjects with metastatic UC had ≥1 detectable CTC (range 1-177). Six subjects had ≥5 CTCs. Fluorescence in situ hybridization analysis was performed in 20 samples from 18 unique subjects using the UroVysion probe set. Copy number gains consistent with neoplasm were observed in those with measurable CTCs but not in any of the CTC-negative samples tested. With a median follow-up of 337 days, all 7 patients with metastasis and detectable CTCs had died compared with 3 (43%) of the 7 with metastasis but without detectable CTCs. CONCLUSION: CTCs are commonly observed in metastatic UC. CTCs were observed in 50% of the patients with metastatic UC tested. Fluorescence in situ hybridization analysis confirmed the aneusomic chromosomal content in the CTCs. These findings suggest that measurable CTCs might be prognostic for shortened survival in patients with metastatic UC, although the optimal threshold for a "positive" finding is unknown. CTCs were also detected in a subset of patients with clinically localized disease, identifying a potential high-risk, preoperative group for future study.
OBJECTIVE: To examine the incidence and prognostic value of circulating tumor cells (CTCs) in urothelial cancer (UC). The detection of CTCs is prognostic in several cancer types. METHODS: A total of 44 subjects with UC were assessed for CTCs using CellSearch Technology and 7.5 mL of peripheral blood, sorted by magnetic separation (epithelial cell adhesion molecule positive) and immunofluorescent staining (positive for cytokeratin 8, 18, or 19, negative for CD45, positive for 4',6-diamidino-2-phenylindole) to identify the CTCs. RESULTS: Five (17%) of 30 subjects with clinically localized and 7 (50%) of 14 subjects with metastatic UC had ≥1 detectable CTC (range 1-177). Six subjects had ≥5 CTCs. Fluorescence in situ hybridization analysis was performed in 20 samples from 18 unique subjects using the UroVysion probe set. Copy number gains consistent with neoplasm were observed in those with measurable CTCs but not in any of the CTC-negative samples tested. With a median follow-up of 337 days, all 7 patients with metastasis and detectable CTCs had died compared with 3 (43%) of the 7 with metastasis but without detectable CTCs. CONCLUSION: CTCs are commonly observed in metastatic UC. CTCs were observed in 50% of the patients with metastatic UC tested. Fluorescence in situ hybridization analysis confirmed the aneusomic chromosomal content in the CTCs. These findings suggest that measurable CTCs might be prognostic for shortened survival in patients with metastatic UC, although the optimal threshold for a "positive" finding is unknown. CTCs were also detected in a subset of patients with clinically localized disease, identifying a potential high-risk, preoperative group for future study.
Authors: Michael Rink; Felix K H Chun; Sarah Minner; Martin Friedrich; Oliver Mauermann; Hans Heinzer; Hartwig Huland; Margit Fisch; Klaus Pantel; Sabine Riethdorf Journal: BJU Int Date: 2010-08-24 Impact factor: 5.588
Authors: David R Shaffer; Margaret A Leversha; Daniel C Danila; Oscar Lin; Rita Gonzalez-Espinoza; Bin Gu; Aseem Anand; Katherine Smith; Peter Maslak; Gerald V Doyle; Leon W M M Terstappen; Hans Lilja; Glenn Heller; Martin Fleisher; Howard I Scher Journal: Clin Cancer Res Date: 2007-04-01 Impact factor: 12.531
Authors: Daniel F Hayes; Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; M Craig Miller; Jeri Matera; W Jeffrey Allard; Gerald V Doyle; Leon W W M Terstappen Journal: Clin Cancer Res Date: 2006-07-15 Impact factor: 12.531
Authors: Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol Journal: J Clin Oncol Date: 2008-07-01 Impact factor: 44.544
Authors: Guangbin Xia; S Ram Kumar; Debra Hawes; Jie Cai; Loubna Hassanieh; Susan Groshen; Sutao Zhu; Rizwan Masood; David I Quinn; Daniel Broek; John P Stein; Parkash S Gill Journal: J Urol Date: 2006-04 Impact factor: 7.450
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Shyamala Maheswaran; Lecia V Sequist; Sunitha Nagrath; Lindsey Ulkus; Brian Brannigan; Chey V Collura; Elizabeth Inserra; Sven Diederichs; A John Iafrate; Daphne W Bell; Subba Digumarthy; Alona Muzikansky; Daniel Irimia; Jeffrey Settleman; Ronald G Tompkins; Thomas J Lynch; Mehmet Toner; Daniel A Haber Journal: N Engl J Med Date: 2008-07-02 Impact factor: 91.245
Authors: Melody Ju; Gary D Kao; David Steinmetz; Sanjay Chandrasekaran; Stephen M Keefe; Thomas J Guzzo; John P Christodouleas; Stephen M Hahn; Jay F Dorsey Journal: Cancer Biol Ther Date: 2014-03-11 Impact factor: 4.742
Authors: Martin Cegan; Katarina Kolostova; Rafal Matkowski; Marek Broul; Jan Schraml; Marek Fiutowski; Vladimir Bobek Journal: Int J Clin Exp Pathol Date: 2014-09-15
Authors: Scott M Langevin; E Andres Houseman; William P Accomando; Devin C Koestler; Brock C Christensen; Heather H Nelson; Margaret R Karagas; Carmen J Marsit; John K Wiencke; Karl T Kelsey Journal: Epigenetics Date: 2014-03-26 Impact factor: 4.528
Authors: Chelsea K Osterman; Jaber Alanzi; James D Lewis; Elizabeth L Kaufman; Vivek Narayan; Ben Boursi; Ravy K Vajravelu; Frank I Scott; S Bruce Malkowicz; Ronac Mamtani Journal: Clin Genitourin Cancer Date: 2017-12-06 Impact factor: 2.872